Literature DB >> 26994148

Ibrutinib responsive central nervous system involvement in chronic lymphocytic leukemia.

Anne Wanquet1, Rudy Birsen2, Richard Lemal3, Mathilde Hunault4, Véronique Leblond2, Thérèse Aurran-Schleinitz1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26994148     DOI： 10.1182/blood-2016-02-697193

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  11 in total

1.  Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvement.

Authors:  Gianluigi Reda; Ramona Cassin; Gabriela Dovrtelova; Cristina Matteo; Juri Giannotta; Maurizio D'Incalci; Agostino Cortelezzi; Massimo Zucchetti
Journal:  Haematologica       Date:  2019-02-14       Impact factor: 9.941

Review 2.  Primary central nervous system lymphoma: essential points in diagnosis and management.

Authors:  Semra Paydas
Journal:  Med Oncol       Date:  2017-03-17       Impact factor: 3.064

Review 3.  Current Treatment of Chronic Lymphocytic Leukemia.

Authors:  Krzysztof Jamroziak; Bartosz Puła; Jan Walewski
Journal:  Curr Treat Options Oncol       Date:  2017-01

4.  Ibrutinib-based therapy for the treatment of marginal zone lymphoma with central nervous system involvement.

Authors:  Fateeha Furqan; Grace Watson; Felipe Samaniego; Luis E Fayad; Michael W Morrison; Philip A Thompson; Raphael E Steiner; Linda Chi; Bouthaina Dabaja; Chelsea C Pinnix; Sattva S Neelapu; Loretta J Nastoupil; Paolo Strati
Journal:  Leuk Lymphoma       Date:  2020-07-10

Review 5.  Biology of CNS lymphoma and the potential of novel agents.

Authors:  James L Rubenstein
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 6.  Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.

Authors:  Andrew Aw; Jennifer R Brown
Journal:  Drugs Aging       Date:  2017-07       Impact factor: 3.923

7.  Successful ibrutinib treatment for central nervous system relapse of chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation.

Authors:  Tomohiko Tanigawa; Masatoshi Sakurai; Jun Kato; Kota Mizuno; Shinya Fujita; Yuya Koda; Taku Kikuchi; Takayuki Shimizu; Shinichiro Okamoto; Keisuke Kataoka
Journal:  Ann Hematol       Date:  2021-07-08       Impact factor: 3.673

8.  Ibrutinib Treatment of Mantle Cell Lymphoma Relapsing at Central Nervous System: A Case Report and Literature Review.

Authors:  Donato Mannina; Barbara Loteta
Journal:  Case Rep Hematol       Date:  2017-07-16

Review 9.  Central nervous system localisation of chronic lymphocytic leukaemia, description of two very distinct cases and a review of the literature.

Authors:  Nyanza K L M Timmers; Josanne S de Maar; Rob C M van Kruijsdijk; Saskia K Klein
Journal:  Ann Hematol       Date:  2018-04-29       Impact factor: 3.673

10.  Successful Treatment of Chronic Lymphocytic Leukemia Multifocal Central Nervous System Involvement with Ibrutinib.

Authors:  Anna Christoforidou; Georgios Kapsas; Zoe Bezirgiannidou; Spyros Papamichos; Ιoannis Kotsianidis
Journal:  Turk J Haematol       Date:  2018-02-02       Impact factor: 1.831
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.